In prostate cancer, in samples harboring a mutant androgen receptor (AR) gene, which are, thus, resistant to the common therapy of AR blockers, the expression levels of Cav3.3 were significantly higher compared to samples negative for AR mutation. Here, AR is linked to prostate cancer.